...
首页> 外文期刊>Alzheimer s Research & Therapy >An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease
【24h】

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease

机译:一种综合的多OMICS方法揭示了阿尔茨海默病的新中枢神经系统途径改变

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Multiple pathophysiological processes have been described in Alzheimer’s disease (AD). Their inter-individual variations, complex interrelations, and relevance for clinical manifestation and disease progression remain poorly understood. We hypothesize that specific molecular patterns indicating both known and yet unidentified pathway alterations are associated with distinct aspects of AD pathology. We performed multi-level cerebrospinal fluid (CSF) omics in a well-characterized cohort of older adults with normal cognition, mild cognitive impairment, and mild dementia. Proteomics, metabolomics, lipidomics, one-carbon metabolism, and neuroinflammation related molecules were analyzed at single-omic level with correlation and regression approaches. Multi-omics factor analysis was used to integrate all biological levels. Identified analytes were used to construct best predictive models of the presence of AD pathology and of cognitive decline with multifactorial regression analysis. Pathway enrichment analysis identified pathway alterations in AD. Multi-omics integration identified five major dimensions of heterogeneity explaining the variance within the cohort and differentially associated with AD. Further analysis exposed multiple interactions between single ‘omics modalities and distinct multi-omics molecular signatures differentially related to amyloid pathology, neuronal injury, and tau hyperphosphorylation. Enrichment pathway analysis revealed overrepresentation of the hemostasis, immune response, and extracellular matrix signaling pathways in association with AD. Finally, combinations of four molecules improved prediction of both AD (protein 14-3-3 zeta/delta, clusterin, interleukin-15, and transgelin-2) and cognitive decline (protein 14-3-3 zeta/delta, clusterin, cholesteryl ester 27:1 16:0 and monocyte chemoattractant protein-1). Applying an integrative multi-omics approach we report novel molecular and pathways alterations associated with AD pathology. These findings are relevant for the development of personalized diagnosis and treatment approaches in AD.
机译:已经在阿尔茨海默病(AD)中描述了多种病理生理方法。他们的个体间变异,复杂的相互关系和临床表现和疾病进展的相关性仍然明白。我们假设表明已知且未识别的途径改变的特定分子模式与AD病理学的独特方面有关。我们在具有正常认知,轻度认知障碍和轻度痴呆症的较良好的老年人队列中的多级脑脊液(CSF)OMIC。用相关性和回归方法分析蛋白质组学,代谢组科,脂族学,单碳代谢和神经炎性相关分子。多OMICS因子分析用于整合所有生物学水平。鉴定的分析物用于构建具有多学会回归分析的广告病理存在和认知下降的最佳预测模型。途径浓缩分析确定了广告中的途径改变。多OMICS集成确定了异质性的五个主要尺寸,解释了队列内的差异和与广告差异相关。进一步的分析暴露于单族常规和不同与淀粉样蛋白病理学,神经元损伤和TAU高磷酸化有关的不同多样性分子鉴定之间的多种相互作用。富集途径分析揭示了与AD相关联的止血,免疫应答和细胞外基质信号传导途径的过度陈述。最后,四个分子的组合改善了AD(蛋白质14-3-3 Zeta / delta,Clusterin,Interehingin-15和Transgelin-2)和认知下降(蛋白质14-3-3 Zeta / delta,Clusterin,Cholesteryl的预测酯27:1 16:0和单核细胞化学蛋白-1)。应用一体化多常规方法我们报告了与广告病理相关的新型分子和途径改变。这些发现与广告中的个性化诊断和治疗方法的开发相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号